Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$1.55 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$7.12M
Enterprise Value-$4.35M
Total Cash (Recent Filing)$29.74M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Jul 30, 2026EPS Estimate
-1.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.07
Shares Outstanding3,612,096
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.36
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$20.00Price Target Upside45.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress (SIM0505)Robust early clinical efficacy (55% ORR across ovarian and uterine serous cohorts) materially derisks the lead ADC program, strengthening the pipeline's clinical validation. Durable positive data can drive partner interest, priority trial enrollment and higher probability of later-stage success, supporting long-term value creation independent of short-term market swings.
Low Financial LeverageModest debt levels and low leverage reduce refinancing and solvency pressure, giving management strategic flexibility to pursue clinical development and partnerships. This structural balance-sheet strength lowers near-term liquidity stress versus peers, improving resilience across 2–6 months as trials progress and funding options are executed.
Expanded Incentive Plan / Governance SupportApproval of an expanded omnibus incentive plan and re-election of directors signals shareholder backing of management and enhances the company's ability to attract and retain scientific and clinical talent. Strong governance continuity and compensation tools support execution through critical development milestones, aiding sustained operational capability.
Bears Say
No Revenue / Sustained LossesAbsence of product revenue and recurring large net losses mean the company remains fully pre-revenue and dependent on external financing. Over months this structural lack of recurring cash inflow increases execution risk and makes clinical timelines and financing execution central to survival and value creation.
Persistent Negative Cash FlowMaterially negative operating and free cash flow creates a sustained funding requirement to maintain R&D and trials. This structural cash burn necessitates periodic capital raises or partnerships, which can dilute shareholders or compress strategic options if markets or partner interest weaken within the next several quarters.
Equity Erosion / Capital DepletionSharp decline in equity over multiple years reflects accumulated losses and capital use, weakening the balance sheet buffer. Reduced equity limits ability to absorb setbacks or fund larger trials without dilutive financing, raising structural vulnerability during pivotal clinical development and regulatory phases.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.55 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $7.12M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Jul 30, 2026 which is in 17 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Apr 30, 2026. The company reported -$1.87 earnings per share for the quarter, beating the consensus estimate of -$2.105 by $0.235.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -1.92.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,612,096 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$1.87 in its last earnings report, beating expectations of -$2.105. Following the earnings report the stock price went up 3.02%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$20.00
▲(45.67% Upside)
Technical Analysis
Ownership Overview
―
Insiders
9.96% Mutual Funds
48.82% Other Institutional Investors
36.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---